Why is SmartECG developed

Why is SmartECG developed 2018-01-23T13:28:16+00:00

Cardiovascular Disease poses a serious health problem in the EU area and also globally

  • Almost 10 % of EU population is affected by CVD.
  • In total almost 49 million people have been diagnosed in EU.
  • In total over 85 million people have been diagnosed in Europe.
  • In EU over 6 million people were diagnosed with CVD in 2015.
  • In Europe over 11 million people were diagnosed with CVD in 2015.
  • CVD is the number one cause of death in most European countries.
  • CVD or CVD-related diseases account for 37 % of deaths in EU (1.8 million people annually) and 45 % of deaths in Europe (3.9 million people annually)

  • Early deaths (under 75 years old): In EU over 400.000 early deaths meaning 26 % of all early deaths, stroke-related deaths account for 59 % of deaths.
  • In Europe over 1.3 million meaning 35 % of all early deaths. Stroke-related deaths account for 51 % of deaths and ischemic heart disease for 49 %.
  • Total CVD costs were 110 billion euros in EU countries 110 billion euros (2015).
  • Costs per capita is EU €218
  • Of CVD costs 51 % is spent in inpatient care and 9 % in primary care.
  • Interpreting the ECG analysis results causes a bottleneck in the primary care level as GPs are not equipped to interpret first ECG analysis results by themselves, and in the secondary care level, as specialist cardiologists are facing a huge data and work overload.
  • In Finland CVD is the fourth most general reason to visit doctor’s appointment (after musculoskeletal and respiratory diseases). It also causes multiple visits: there were on average 5 visits per person to nurse appointment due to palpitations *
  • Today 8 million tests performed annually in Europe, estimated to grow to 11 million analyses by 2020 (due to advancements in patient-friendly analysis tools and increased number of CVD patients).
  • Global ECG management systems market will grow to €180 million by 2020. **

The direct impacts and their related effects from SmartECG are:

1. BETTER TREATMENT OF CARDIOVASCULAR DISEASES

  • More accurate and faster diagnosis by more comprehensive and detailed ECG analysis
  • Lower mortality rate and increased life-expectancy of CVD patients

2. INCREASED PATIENT-FRIENDLINESS

  • Reduced healthcare waiting times, increased accessibility to specialist care
  • Wider implementation of remote (home-) monitoring practices
  • Reduced travel costs and time

3. HIGHER MEDICAL PROFESSIONALITY

  • Empowered primary and secondary care specialists in CVD diagnosing and monitoring
  • Increased collaboration and sharing practices between GPs and specialist physicians

4. MORE EFFICIENT HEALTHCARE SYSTEM

  • Improved and more competent primary care level
  • Shorter waiting lists, increased patients throughput
  • Lower cost per patient and reduced CVD treatment expenditures
  • Increased international cooperation and free movement of healthcare services in EU
  • Standardised ECG analysis output for best compatibility with various eHealth solutions

People die of CVD

0%
1990
0%
2015
0%
2030

Million of people

0
2000
0
2015
0
2030

Recent Posts

Contact Info

Lars Sonckin kaari 10 – 16
02600 Espoo
FINLAND

Phone:
+358 (0) 45 2300 520